Tenvir

Tenvir is an antiretroviral medication that treats HIV-1 in adults when taken with other anti-HIV drugs. One pill contains 300mg of Tenofovir Disoproxil Fumarate. It is highly effective, yet Tenvir must be part of a regiment of multiple antiretrovirals to stop HIV-1 from progressing to AIDS. One 300mg pill should be consumed orally with or without food once a day. Because Tenvir has been documented to affect kidney functions, patients with a creatinine clearance of 30-49 mL/min should only take one dose every 48 hours. Those with a creatinine clearance of 10-29 mL/min may take one 300 mg pill two times a week, while patients undergoing hemodialysis should be restricted to one pill every seven days or 12 hours after dialysis. Anyone hypersensitive to Tenofovir Disoproxil Fumarate should not take Tenvir. Several mild side effects have been commonly reported by patients taking Tenvir including: nausea, rash, diarrhea, asthenia, vomiting, flatulence. Some less common but severe side effects that have been documented are: renal impairment or failure, interstitial nephritis, fanconi syndrome, hepatomegaly with steatosis, lactic acidosis, tubular necrosis, nephrogenic diabetes insipidus. Other adverse effects have been reported by patients taking Tenvir. Let your doctor know if you experience any changes in your physical or mental health after beginning to take Tenvir. Some patients show symptoms of immune reconstitution syndrome when first starting Tenvir. Patients with hepatitis B can experience acute exacerbation of hepatitis symptoms after they discontinue Tenvir. The safety and effectiveness of administering Tenvir to patients co-infected with hepatitis B and HIV has yet be established, and hepatitis patients should be closely monitored for several months after they stop using Tenvir. Patients taking Tenvir have also reported loss in bone mineral density and osteomalacia. Taking nephrotoxic drugs with Tenvir might increase the risk of renal implications. Tenvir should not be taken with didanosine, lamivudine or abacavir because these drugs can sometimes render Tenvir ineffective. Co-administering atazanavir or lopinavir/ritonavir with Tenvir can worsen the side effects of Tenvir. Tenvir should be discontinued if this occurs. Tenvir can decrease the AUC and Cmin of atazanavir; atazanavir without ritonavir should not be co-administered with Tenvir. Laboratory testing has revealed no increased risk of birth defects when administering Tavin to pregnant animals, and no reports of birth defects related to taking Tenvir have been documented in humans; however, new mothers are discouraged from breastfeeding due to the possible risk of transmitting HIV to their infant. Patients who take more than their prescribed dose of Tenvir should be monitored for toxicity. The patient may have to undergo haemodialysis to purge the excess medication from their body.